Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Novel Anti-cd38 antibodies for the treatment of cancer

an anti-cd38 and cancer technology, applied in the introduction of vector-based foreign material, antibody medical ingredients, animal cells, etc., can solve the problem of presence, and achieve the effect of less immunogenicity and improved properties

Inactive Publication Date: 2011-10-27
SANOFI SA
View PDF8 Cites 30 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The invention provides antibodies that can kill CD38+ cells, such as lymphoma cells, leukemia cells, and multiple myeloma cells, by inducing apoptotic cell death. These antibodies can kill CD38+ cells even in the absence of stroma cells or stroma-derived cytokines. The antibodies can be polyclonal or monoclonal, and they can be humanized versions of previously known antibodies. The invention also contemplates the use of conjugates between the CD38+ cell binding agent and a cytotoxic agent, which can form effective killing agents. Overall, the invention provides new tools for the treatment of CD38+ cell-related diseases.

Problems solved by technology

However, they can only do so in the presence of stroma cells or stroma-derived cytokines.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel Anti-cd38 antibodies for the treatment of cancer
  • Novel Anti-cd38 antibodies for the treatment of cancer
  • Novel Anti-cd38 antibodies for the treatment of cancer

Examples

Experimental program
Comparison scheme
Effect test

example 1

Mouse CD38 Antibodies

[0360]300-19 cells, a pre-B cell line derived from a Balb / c mouse (M. G. Reth et al. 1985, Nature, 317: 353-355), stably expressing a high level of human CD38 were used for immunization of Balb / c VAF mice. Mice were subcutaneously immunized with about 5×106 CD38-expressing 300-19 cells per mouse every 2-3 weeks by standard immunization protocols used at ImmunoGen, Inc. The immunized mice were boosted with another dose of antigen three days before being sacrificed for hybridoma generation. The spleen from the mouse was collected according to standard animal protocols and was ground between two sterile, frosted microscopic slides to obtain a single cell suspension in RPMI-1640 medium. The spleen cells were pelleted, washed, and fused with murine myeloma P3X63Ag8.653 cells (J. F. Kearney et al. 1979, J Immunol, 123: 1548-1550) by using polyethylene glycol-1500 (Roche 783 641). The fused cells were resuspended in RPMI-1640 selection medium containing hypoxanthine-am...

example 2

Binding Characterization of Anti-CD38 Antibodies

[0362]FACS histograms demonstrating the binding of anti-CD38 antibodies, 38SB13, 38SB18, 38SB19, 38SB30, 38SB31, and 38SB39 to CD38-expressing 300-19 cells and the absence of binding to the parental 300-19 cells are shown in FIG. 1. 38SB13, 38SB18, 38SB19, 38SB30, 38SB31, or 38SB39 antibody (10 nM) was incubated for 3 h with either CD38-expressing 300-19 cells or the parental 300-19 cells (1-2×105 cells per sample) in 100 μL ice-cold RPMI-1640 medium supplemented with 2% normal goat serum. Then, the cells were pelleted, washed, and incubated for 1 h on ice with FITC-conjugated goat anti-mouse IgG-antibody (Jackson Laboratory, 100 μL, 6 μg / mL in cold RPMI-1640 medium supplemented with 2% normal goat serum). The cells were pelleted again, washed, resuspended in 200 μL of PBS containing 1% formaldehyde, and analyzed using a FACSCalibur flow cytometer with CellQuest software (BD Biosciences).

[0363]The FACS histograms of CD38-expressing 300...

example 3

Induction of Apoptosis of Ramos and Daudi Lymphoma Cells, by 38Sb13, 38Sb18, 38SB19, 38SB30, 38SB31, and 38SB39 Antibodies

[0365]The anti-CD38 antibodies, 38SB13, 38SB18, 38SB19, 38SB30, 38SB31, and 38SB39 induced apoptosis of Ramos and Daudi (ATCC CCL-213) lymphoma cell lines and the MOLP-8 multiple myeloma cell line (DSMZ ACC 569). The degree of apoptosis was measured by FACS analysis after staining with FITC conjugates of Annexin V (Biosource PHN1018) and with TO-PRO-3 (Invitrogen T3605). Annexin V binds phosphatidylserine on the outside but not on the inside of the cell membrane bilayer of intact cells. In healthy, normal cells, phosphatidylserine is expressed on the inside of the membrane bilayer, and the transition of phosphatidylserine from the inner to the outer leaflet of the plasma membrane is one of the earliest detectable signals of apoptosis. Binding of Annexin V is thus a signal for the induction of apoptosis. TO-PRO-3 is a monomeric cyanine nucleic acid stain that can ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pharmaceutical compositionaaaaaaaaaa
affinityaaaaaaaaaa
volumeaaaaaaaaaa
Login to View More

Abstract

Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of killing CD38+ cells by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and / or complement-dependent cytotoxicity (CDC). Said antibodies and fragments thereof may be used in the treatment of tumors that express CD38 protein, such as multiple myeloma, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia, or acute lymphocytic leukemia, or the treatment of autoimmune and inflammatory diseases such as systemic lupus, rheumatoid arthritis, multiple sclerosis, erythematosus, and asthma. Said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of CD38. Also provided are cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the CD38 protein.

Description

BACKGROUND OF THE INVENTION[0001]CD38 is a 45 kD type II transmembrane glycoprotein with a long C-terminal extracellular domain and a short N-terminal cytoplasmic domain. The CD38 protein is a bifunctional ectoenzyme that can catalyze the conversion of NAD+ into cyclic ADP-ribose (cADPR) and also hydrolyze cADPR into ADP-ribose. During ontogeny, CD38 appears on CD34+ committed stem cells and lineage-committed progenitors of lymphoid, erythroid and myeloid cells. CD38 expression persists mostly in the lymphoid lineage with varying expression levels at different stages of T and B cell development.[0002]CD38 is upregulated in many hematopoeitic malignancies and in cell lines derived from various hematopoietic malignancies, including non-Hodgkin's lymphoma (NHL), Burkitt's lymphoma (BL), multiple myeloma (MM), B chronic lymphocytic leukemia (B-CLL), B and T acute lymphocytic leukemia (ALL), T cell lymphoma (TCL), acute myeloid leukemia (AML), hairy cell leukemia (HCL), Hodgkin's Lymphom...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395C12N15/85C12N5/10C07K16/40A61P35/00C07H21/04A61P19/02A61P1/00A61P1/04A61P25/00A61P11/06G01N33/574A61P35/02
CPCA61K2039/505C07K2317/732C07K2317/24G01N2333/924C07K2317/30C07K2317/565G01N33/57426C07K16/462C07K2317/56G01N33/57484C07K2317/734C07K16/2896C07K2317/34C07K2317/73A61K47/6803A61K47/6867A61P1/00A61P1/04A61P1/16A61P11/00A61P11/06A61P13/12A61P17/00A61P17/04A61P19/02A61P21/00A61P25/00A61P27/02A61P29/00A61P35/00A61P35/02A61P37/00A61P37/02A61P37/06A61P43/00A61P7/04A61P9/00A61K47/68033A61K47/68035A61K39/395C07K16/28
Inventor PARK, PETER U.BARTLE, LAURASKALETSKAYA, ANNAGOLMAKHER, VIKTORTAVARES, DANIELDECKERT, JUTTAMILOL, VINCENTBLANC, VERONIQUE
Owner SANOFI SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com